https://www.selleckchem.com/pr....oducts/Sunitinib-Mal
tive participants had lower risk for developing CKD compared with inactive participants. Canagliflozin reduces the risk for cardiovascular and kidney outcomes in type 2 diabetes. This study aimed to assess the relative and absolute effects of canagliflozin on clinical outcomes across different KDIGO (Kidney Disease Improving Global Outcomes) risk categories based on estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio. Post hoc analysis of the CANagliflozin cardioVascular Assessment Study (C
Like
Comment
Share
